PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
0.7025
-0.0185 (-2.57%)
At close: Feb 20, 2026, 4:00 PM EST
0.7379
+0.0354 (5.04%)
After-hours: Feb 20, 2026, 7:29 PM EST

PharmaCyte Biotech Cash Flow Statement

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '25 Apr '25 Apr '24 Apr '23 Apr '22 Apr '21
Net Income
-7.0730.660.33-4.32-4.24-3.55
Asset Writedown & Restructuring Costs
--2---
Loss (Gain) From Sale of Investments
-6.6-26.531.57---
Stock-Based Compensation
0.260.480.670.650.110.44
Other Operating Activities
8.04-8.94-7.030.17--0.08
Change in Accounts Payable
0.590.010.26-0.240.03-0.01
Change in Other Net Operating Assets
0.271.350.04-0.05-0.02-0.13
Operating Cash Flow
-4.52-2.98-2.15-3.79-4.12-3.33
Investment in Securities
-3-7----
Other Investing Activities
---5---
Investing Cash Flow
-3-7-5---
Long-Term Debt Repaid
-----0.05-0.06
Total Debt Repaid
-----0.05-0.06
Net Debt Issued (Repaid)
-----0.05-0.06
Issuance of Common Stock
--0087.364.7
Repurchase of Common Stock
-0.4-2.54-28.2-13.56--
Financing Cash Flow
2.09-25.03-10.71-13.5687.314.64
Foreign Exchange Rate Adjustments
-0-0-0-0.0100
Net Cash Flow
-5.43-35.01-17.86-17.3683.21.31
Cash Interest Paid
----00
Cash Income Tax Paid
--0-00
Levered Free Cash Flow
-7.51-13.343.28-3.52-2.62-1.97
Unlevered Free Cash Flow
-7.51-13.343.28-3.52-2.62-1.97
Change in Working Capital
0.851.360.3-0.30.01-0.15
Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q